BPC-157: peptide identity, purity, and stability

What BPC-157 is

BPC-157 is a synthetic peptide of fifteen amino acid residues. Its name is an abbreviation of "body protection compound," and the numbered designation refers to a partial sequence of a larger protein originally characterised in gastric juice. The material supplied for laboratory work is made by solid-phase peptide synthesis rather than extracted from tissue, which is why its documentation looks like that of any other synthetic peptide: a synthesis record, a chromatographic purity determination, and a mass-spectrometry identity confirmation.

The residue sequence, written in the standard single-letter notation, is GEPPPGKPADDAGLV. In three-letter notation that is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence is worth knowing because it explains most of what appears on an analytical report for this material, including which impurities are likely and why the peptide behaves as it does on a reversed-phase column.

Treat the figures above as orientation, not as a substitute for the report that accompanies a given lot. The certificate for the specific lot in hand is the authoritative record, and where a published report disagrees with this page, the report governs.

Why the sequence predicts the impurity profile

Three features of GEPPPGKPADDAGLV determine what a chromatogram of this peptide tends to look like.

• A proline-rich stretch. Positions three, four, and five are consecutive prolines, with two more prolines later in the chain. Proline couples less efficiently than most residues during synthesis, so deletion sequences — chains missing one residue — are the most common synthesis-related impurity in this material. On a chromatogram they usually appear as peaks eluting close to the main peak rather than far from it, because a fifteen-residue chain missing one residue is chemically very similar to the complete chain.
• Two adjacent aspartic acid residues. Positions ten and eleven are both aspartate. Aspartate-containing sequences are prone to forming a cyclic intermediate that can rearrange the backbone, producing a species with the same mass as the parent peptide but different chromatographic behaviour. This matters for interpretation: mass spectrometry alone will not distinguish it, which is one of the clearest practical reasons a report needs both an identity result and a purity result rather than either on its own.
• No cysteine and no methionine. The sequence contains neither of the two residues most vulnerable to oxidation. Oxidation-related impurity peaks, which dominate the degradation profile of many other research peptides, are therefore not the primary concern for this one. Its stability profile is driven by moisture and by the aspartate chemistry above.

For how these peaks are measured and reported, see how to read an HPLC chromatogram.

How identity is established

Purity and identity are separate questions answered by separate instruments, and a report that gives only one of them is incomplete.

Identity can be established two ways, and it is worth knowing which one a given report used. Mass spectrometry measures the mass-to-charge ratio of the ionised peptide and compares the observed mass against the mass calculated from the stated formula. Retention-time matching compares where the main peak elutes against a reference standard run under the same method; agreement is strong evidence of identity for a known sequence, and it is the method reported as HPLC-RTM on a certificate.

Neither settles the aspartate question on its own. Mass agreement does not exclude a rearranged species of identical mass, and retention-time agreement is what would separate them — which is the practical reason the chromatogram is read alongside the identity line rather than instead of it. Arctic Lab Supply's reports state identity as HPLC-RTM, and the chromatogram is published with them so the peak pattern can be read directly.

Purity is established by reversed-phase high-performance liquid chromatography. The sample is separated on a column, every component that reaches the detector is integrated, and the purity figure is the area of the main peak as a percentage of all integrated area. A figure quoted without the chromatogram behind it cannot be checked. HPLC purity versus mass-spectrometry identity covers what each result does and does not establish.

Stability and storage of the lyophilized solid

BPC-157 is supplied as a lyophilized solid, and in that state it is comparatively robust. The freeze-drying step removes the water that drives the principal degradation pathways, which is why sealed vials are stored and shipped as a solid rather than in solution.

Two conditions matter for a sealed vial in storage. The first is temperature: colder storage slows every chemical process available to the peptide, and laboratories generally hold long-term stock frozen rather than at ambient temperature. The second, and the one more often underestimated, is moisture. A lyophilized peptide is hygroscopic — it draws water out of the air. A vial brought from cold storage into a warm room will condense atmospheric moisture on and in the solid if it is opened before it has equilibrated to room temperature, and that adsorbed water is what allows the aspartate rearrangement described above to proceed in what is nominally a dry solid.

Stability is a documented property, not an assumed one. A laboratory establishes it by holding material under defined conditions and re-analysing it at intervals, then reporting what changed. Where a supplier states a retest date or a storage condition, ask what data supports it. Storing lyophilized research materials covers the general case.

What the published literature covers

The research record on BPC-157 is almost entirely preclinical. Published work is dominated by rodent studies and by in vitro systems, with a substantial share of the literature originating from a small number of research groups. Reported areas of investigation include tissue repair models, gastrointestinal models, and vascular response, and this body of work is the reason the compound is requested by laboratories.

Three characteristics of that literature are worth stating plainly, because they are frequently omitted in descriptions of this material:

• The compound has not completed the regulatory process that would establish safety or efficacy for any medical indication, and it is not an approved medicine in any jurisdiction.
• Findings in rodent and cell-culture models do not transfer automatically to other species. A result reported in a rat model is a result in a rat model.
• Concentration of the literature within a limited number of groups means independent replication is a reasonable thing to look for when reading it.

Arctic Lab Supply does not publish research conclusions, recommend applications, or provide guidance on experimental design. This page exists to describe the material and its documentation.

Reading the batch documentation for a lot

Each lot supplied carries its own report, and the report is specific to that lot rather than to the product line. Four checks apply to a BPC-157 certificate in particular:

1. The lot identifier on the report matches the vial label. A report for a different lot describes different material, however similar the two may be. See lot traceability.
2. The stated formula and observed mass agree. For this peptide the calculated mass is approximately 1,419 g/mol; the observed value should sit within the method's tolerance of it.
3. The chromatogram is present, not just the number. Peaks eluting immediately adjacent to the main peak are the expected signature for a proline-rich sequence, and their size is more informative than the headline percentage on its own.
4. The integrated areas account for the whole run. If the percentages do not total 100, the report should state what was excluded and why.

Related documentation